CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
By
[email protected] (Erin Kennedy)
2d agoen
Source
BarsCRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?fool.comOne company leads in gene-editing approvals, while the other targets surging demand in metabolic treatments. Here’s how their financials and risk profiles compare.
You might also wanna read
CRISPR’s next act: the companies editing the epigenome to treat disease
nature.com·9d ago
STAT+: Roche drug sets new standard for KRAS-driven lung cancer
STAT·6d ago
Manufacturing and regulatory hurdles threaten cell and gene therapy progress
The article discusses how manufacturing and regulatory challenges are hindering the progress of cell and gene therapies, particularly in can
medium.com·24d ago
FDA Draft Guidance Allows Gene Therapy Companies to Leverage Existing Data for Faster Product Approvals
The FDA released a new draft guidance on June 2 titled "Leveraging Prior Knowledge in the Development of Human Gene Therapy Products Incorpo
jdsupra.com·26d ago
Daily briefing: Editing the epigenome with CRISPR to treat disease
Nature Communications·9d ago
CRISPR’s next act: the companies editing the epigenome to treat disease
go.nature.com·7d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.